Related Experiment Video
Updated: Jan 14, 2026

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
Published on: May 17, 2018
The Impact of Fatigue on Health, Function, and Survival Between Ages 70 and 100
Irit Stessman Lande1, Aliza Rozenberg2, Jochanan Stessman1
1The Jerusalem Institute of Aging Research, Hadassah Medical Center, Mt. Scopus, Jerusalem, Israel; Department of Geriatric Rehabilitation and the Center for Palliative Care, Faculty of Medicine, Hebrew University of Jerusalem, and Hadassah Medical Center, Mt. Scopus, Jerusalem, Israel.
Objective:
Although fatigue is common with aging, its association with health outcomes throughout the entire aging life span have been poorly described. This longitudinal study aimed to examine the trajectory of fatigue between ages 70 and 100, and its long-term impact on health, function, and survival.
Design:
The Jerusalem Longitudinal Study is a prospective longitudinal cohort study, spanning 1990 to 2022.
Setting And Participants:
A representative sample of community-dwelling Jerusalem residents, born 1920-1921, examined at ages 70, 78, 85, 90, 95, and 100 (n = 604, 1024, 1222, 729, 508, and 205, respectively).
Methods:
Comprehensive assessment included fatigue and various medical, functional, cognitive and social variables. Risk of fatigue for different outcomes, including health, function, and mortality, was analyzed using multivariate logistic and Cox proportional hazards models adjusting for known risk factors.
Results:
At ages 70, 78, 85, 90, 95, and 100, the prevalence of fatigue was 29.4%, 52.3%, 67.9%, 77.2%, 64.9%, and 65.6%. Between age 70 and 100, fatigue was significantly associated with numerous cross-sectional health and functional measures, and subsequent deterioration for loneliness, self-rated health, dependence in activities of daily living, and physical activity. In contrast, no consistent pattern of association with current or subsequent common medical morbidities was observed. Significantly decreased survival rates were observed among fatigued vs nonfatigued subjects at ages 70-78, 78-85, 85-90, and 90-95: 69.6% vs 80.8% (P = .008), 64.9% vs 73.3% (P = .002), 60.6% vs 76.4% (P < .001), and 51.3% vs 65.0% (P = .007), respectively, yet not at ages 95-100: 21.7% vs 18.8% (P = .99). After adjusting for known mortality risk factors, fatigue at ages 70, 85, and 90 was associated with increased mortality.
Conclusions And Implications:
Our findings highlight the clinical importance of recognizing fatigue throughout the entire aging life span as an independent marker for subsequent negative health outcomes and mortality. Although fatigue might serve as a surrogate for intrinsic capacity, it remains unclear if fatigue is amenable to intervention.
More Related Videos
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
09:25The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
Published on: May 31, 2016
Related Concept Videos
The Effect of Aging on Tissues
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Fatigue
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism